Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. written informed consent;~2. ≥18 years of age;~3. a bacterial infection of the skin with a lesion size area of at least 75 cm2;~4. a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;~5. the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain).~Exclusion Criteria:~1. severely impaired arterial blood supply such that amputation of the infected anatomical site is likely;~2. infected diabetic foot ulcers;~3. infected decubitus ulcers;~4. necrotizing fasciitis or gangrene;~5. uncomplicated skin or skin structure infection;~6. infections associated with a prosthetic device;~7. suspected or confirmed osteomyelitis;~8. conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iclaprim (Type: EXPERIMENTAL): iclaprim 80 mg intravenous every 12 hours
- vancomycin (Type: ACTIVE_COMPARATOR): vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance

Based on this trial design, predict the completion outcome and termination type (if applicable).